Almirall, S.A. reported first-quarter 2026 results led by continued expansion in its European Dermatology business, with Ebglyss and Ilumetri remaining the central commercial growth drivers. The Barcelona-based medical dermatology company said European Dermatology sales rose 19.3% year over year to €166.3 million, while total net sales increased 2.2% to €291 million in a quarter shaped by biologics momentum, broader portfolio growth, and continued pipeline investment.
Why Almirall’s European dermatology growth matters more than the headline sales number suggests
The most important signal in Almirall’s Q1 2026 results is not the modest 2.2% rise in group net sales, but the much stronger performance of the European Dermatology business. That gap matters because it shows the strategic center of gravity shifting further toward medical dermatology, where Almirall has been trying to build a more defensible position through biologics, lifecycle management, and specialty product depth. For a pharmaceutical company of Almirall’s scale, growth quality can matter as much as growth rate, particularly when the stronger-performing division is also the area where management is concentrating pipeline and partnership resources.
The headline sales figure is also affected by prior-period comparison dynamics, including the impact of a divestment or outlicensing in Q1 2025. That makes the underlying dermatology trend more useful for industry observers than the consolidated top-line percentage alone. European Dermatology now appears to be the clearest expression of Almirall’s strategy: build a specialist portfolio in inflammatory and immune-mediated skin diseases, use commercial execution to scale launched assets, and extend the opportunity through additional indications and new mechanisms.
The risk is that this strategy increases dependence on a narrower therapeutic identity. Almirall’s sharper focus gives the company more credibility with dermatologists, payers, and development partners, but it also makes execution failures more visible. If biologics growth slows, if new indication expansion takes longer than expected, or if competitive pressure rises in atopic dermatitis and psoriasis, the same concentration that currently supports the investment case could become a source of vulnerability.
How Ebglyss is becoming a major test of Almirall’s biologics execution in atopic dermatitis
Ebglyss, the lebrikizumab product used for systemic treatment of moderate-to-severe atopic dermatitis, delivered €41.9 million in quarterly sales, more than doubling year over year. That scale-up is significant because atopic dermatitis is no longer a single-product biologics market with limited therapeutic choice. Dermatologists now weigh efficacy, dosing convenience, durability, safety profile, patient adherence, payer access, and real-world outcomes when choosing among advanced systemic therapies.
Almirall’s disclosed performance suggests Ebglyss is gaining traction in recent launch countries, supported by sustained patient need and expanding market access. This is commercially meaningful because biologics in atopic dermatitis often require more than regulatory approval to build durable adoption. Physicians need confidence in disease control, payers need evidence that the product can justify its cost, and patients need a treatment experience that supports persistence over time.
The unresolved question is how much of the early growth reflects launch momentum versus durable market share capture. Strong post-launch uptake can flatten once the most accessible patient segments are reached. For Almirall, the next phase will likely depend on maintaining physician confidence, expanding evidence across age groups and disease settings, and defending Ebglyss against established and emerging competitors. Positive pediatric and long-term disease control data can help, but commercial durability will require consistent access, patient retention, and differentiation in crowded clinical decision pathways.
Why Ilumetri still matters in psoriasis despite a more mature biologics market
Ilumetri, the tildrakizumab product used for systemic treatment of moderate-to-severe psoriasis, posted €61.6 million in Q1 2026 net sales, representing 11.8% year-over-year growth. That performance is notable because psoriasis is a comparatively mature biologics category, with several strong anti-IL-23 and related immunology assets already embedded in specialist practice. Growth in this setting usually depends less on novelty and more on clinical confidence, persistence, positioning, and payer familiarity.
The continued double-digit growth of Ilumetri suggests Almirall still has room to extract value from a well-established psoriasis asset. Anti-IL-23 therapies remain clinically relevant because they are associated with strong disease control in many patients, and psoriasis treatment decisions often reward products that combine specialist familiarity with durable outcomes. The final two-year POSITIVE study results on patient wellbeing, presented through the company’s dermatology evidence program, also point toward Almirall’s attempt to build value beyond skin clearance metrics alone.
The limitation is that psoriasis biologics are not an easy category in which to sustain momentum indefinitely. Competition is intense, switching dynamics are complex, and payers continue to scrutinize high-cost chronic therapies. Almirall’s ability to keep Ilumetri growing will depend on whether evidence generation and commercial execution can preserve relevance as newer mechanisms and biosimilar pressures reshape parts of the immunology landscape.
Why the broader dermatology portfolio gives Almirall useful depth beyond biologics
Almirall’s broader dermatology portfolio also contributed to Q1 2026 momentum, with Wynzora delivering €9.3 million in net sales and Klisyri reaching €7.4 million. These products do not carry the same strategic visibility as Ebglyss or Ilumetri, but they matter because they broaden the company’s dermatology footprint across conditions such as psoriasis and actinic keratosis. In specialty dermatology, portfolio breadth can improve the productivity of commercial infrastructure by giving sales teams more reasons to engage clinicians across multiple disease areas.
This matters for Almirall’s positioning as a medical dermatology partner rather than a company dependent on one or two flagship products. A broader portfolio can also reduce some concentration risk, even if the sales contribution remains smaller than that of the leading biologics. For dermatology practices, product breadth can reinforce familiarity with the company’s scientific and commercial presence, especially when accompanied by education platforms, real-world evidence, and continued lifecycle support.
The risk is that smaller dermatology brands can be overshadowed by biologics in both investor narratives and resource allocation. If Almirall directs too much attention to the highest-growth assets, mature or mid-sized products could lose promotional support. Conversely, if resources are spread too thinly, the company may dilute its ability to scale the most strategically important launches. The balance between portfolio breadth and biologics focus will remain important in 2026.
How Almirall’s pipeline progress could shape its long-term medical dermatology identity
Almirall’s R&D update adds a second layer to the Q1 2026 story. The initiation of a Phase I study for an anti-IL-13/OX40L bispecific antibody indicates that the company is looking beyond current marketed biologics toward differentiated immunology assets. The collaboration with China-based Huaota on a novel monoclonal antibody also shows that Almirall is using external partnerships to supplement internal development capacity.
The clinical logic is clear. Dermatology is increasingly being shaped by immune pathway precision, with companies looking for mechanisms that can address disease heterogeneity, improve response depth, or serve patients who do not respond adequately to existing therapies. A bispecific approach targeting IL-13 and OX40L could be strategically interesting if it eventually demonstrates meaningful differentiation, although early-phase programs carry a high degree of scientific and regulatory uncertainty.
That uncertainty is the key point. Phase I initiation is a sign of progress, not proof of clinical competitiveness. The path from early human testing to dermatology market relevance is long, expensive, and crowded with failure risk. For Almirall, the pipeline’s value will depend on whether these programs can move into proof-of-concept studies with clean safety signals, credible efficacy endpoints, and a practical development path in indications where payer and clinician demand remains strong.
Why 2026 guidance keeps investor attention on execution rather than reinvention
Almirall reiterated full-year 2026 guidance for 9% to 12% net sales growth and EBITDA of €270 million to €290 million. That guidance frames the Q1 update as a steady execution story rather than a dramatic reset. EBITDA of €67.5 million represented 23.2% of net sales, improving versus the full-year 2025 EBITDA margin level, although total EBITDA was lower year over year in the quarter.
For investors and industry observers, the key tension is between margin discipline and growth investment. Dermatology biologics require commercial spending, evidence generation, market access work, and post-launch lifecycle support. Pipeline expansion also requires capital, especially if Almirall intends to move additional programs into Phase II proof-of-concept studies during 2026. The company’s ability to protect EBITDA while funding medical dermatology expansion will be central to how the market reads the 2026 outlook.
The approved flexible dividend of €0.19 per share adds another capital allocation dimension. It signals continuity and shareholder returns, but it also sits alongside an innovation strategy that requires sustained investment. Almirall does not need to choose between dividends and R&D in the near term, but the balance will become more important if pipeline costs rise or if biologics growth requires heavier market access spending.
What clinicians, regulators, and industry observers are likely to watch next
The next phase of Almirall’s story will likely be judged by three signals: whether Ebglyss can sustain post-launch growth, whether Ilumetri can remain resilient in a mature psoriasis market, and whether early-stage pipeline assets can produce credible proof-of-concept momentum. The company’s near-term performance is being powered by commercial execution, but its longer-term valuation narrative will depend on whether Almirall can convert dermatology specialization into durable innovation.
Clinicians will watch the strength of long-term disease control data, pediatric and adolescent evidence, and expansion into adjacent conditions such as nummular eczema. Regulators will focus on safety, endpoint clarity, and whether new mechanisms offer enough differentiation to justify development in crowded treatment categories. Industry observers will watch whether the Huaota collaboration and anti-IL-13/OX40L program signal a broader shift toward externally reinforced innovation.
Almirall’s Q1 2026 results therefore tell a story of focused momentum, not transformation. The dermatology engine is performing well, Ebglyss is becoming a more important growth driver, Ilumetri remains commercially relevant, and the pipeline is moving forward. The tougher question is whether this momentum can mature into a stronger long-term platform in medical dermatology, where scientific differentiation, access strategy, and clinical trust will decide how much of today’s growth can be sustained.
